Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dirk Huebner, Abraham Fong, Anas Younes

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.

Original languageEnglish (US)
Pages (from-to)1562-1566
Number of pages5
JournalBlood
Volume128
Issue number12
DOIs
StatePublished - Sep 22 2016

Fingerprint

Hodgkin Disease
Refractory materials
Durability
Survival
Stem cells
Disease control
Transplants
Confidence Intervals
Disease-Free Survival
Survival Rate
cAC10-vcMMAE
Hematopoietic Stem Cell Transplantation
Peripheral Nervous System Diseases
Hematopoietic Stem Cells
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. / Chen, Robert; Gopal, Ajay K.; Smith, Scott E.; Ansell, Stephen M.; Rosenblatt, Joseph D; Savage, Kerry J.; Connors, Joseph M.; Engert, Andreas; Larsen, Emily K.; Huebner, Dirk; Fong, Abraham; Younes, Anas.

In: Blood, Vol. 128, No. 12, 22.09.2016, p. 1562-1566.

Research output: Contribution to journalArticle

Chen, R, Gopal, AK, Smith, SE, Ansell, SM, Rosenblatt, JD, Savage, KJ, Connors, JM, Engert, A, Larsen, EK, Huebner, D, Fong, A & Younes, A 2016, 'Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma', Blood, vol. 128, no. 12, pp. 1562-1566. https://doi.org/10.1182/blood-2016-02-699850
Chen, Robert ; Gopal, Ajay K. ; Smith, Scott E. ; Ansell, Stephen M. ; Rosenblatt, Joseph D ; Savage, Kerry J. ; Connors, Joseph M. ; Engert, Andreas ; Larsen, Emily K. ; Huebner, Dirk ; Fong, Abraham ; Younes, Anas. / Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. In: Blood. 2016 ; Vol. 128, No. 12. pp. 1562-1566.
@article{ecde9a4089f145429f54bfb6e85dbd7f,
title = "Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma",
abstract = "Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41{\%} (95{\%} confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22{\%} (95{\%} CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64{\%} (95{\%} CI: 48-80{\%}) and 52{\%} (95{\%} CI: 34-69{\%}), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38{\%} of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9{\%} of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88{\%} experienced either resolution (73{\%}) or improvement (14{\%}) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.",
author = "Robert Chen and Gopal, {Ajay K.} and Smith, {Scott E.} and Ansell, {Stephen M.} and Rosenblatt, {Joseph D} and Savage, {Kerry J.} and Connors, {Joseph M.} and Andreas Engert and Larsen, {Emily K.} and Dirk Huebner and Abraham Fong and Anas Younes",
year = "2016",
month = "9",
day = "22",
doi = "10.1182/blood-2016-02-699850",
language = "English (US)",
volume = "128",
pages = "1562--1566",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

AU - Chen, Robert

AU - Gopal, Ajay K.

AU - Smith, Scott E.

AU - Ansell, Stephen M.

AU - Rosenblatt, Joseph D

AU - Savage, Kerry J.

AU - Connors, Joseph M.

AU - Engert, Andreas

AU - Larsen, Emily K.

AU - Huebner, Dirk

AU - Fong, Abraham

AU - Younes, Anas

PY - 2016/9/22

Y1 - 2016/9/22

N2 - Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.

AB - Presented here are the 5-year end-of-study results from the pivotal phase 2 trial of brentuximab vedotin in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) after failed hematopoietic autologous stem cell transplantation. At 5 years, the overall patient population (N = 102) had an estimated overall survival (OS) rate of 41% (95% confidence interval [CI]: 31-51) and progression-free survival (PFS) rate of 22% (95% CI: 13-31). Patients who achieved a complete response (CR) to brentuximab vedotin (N = 34) had estimated OS and PFS rates of 64% (95% CI: 48-80%) and 52% (95% CI: 34-69%), respectively. The median OS and PFS were not reached in CR patients, with 13 patients (38% of all CR patients) remaining in follow-up and in remission at study closure. Of the 13 patients, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) remain in sustained CR without receiving any further anticancer therapy after treatment with brentuximab vedotin. Of the patients who experienced treatment-emergent peripheral neuropathy, 88% experienced either resolution (73%) or improvement (14%) in symptoms. These 5-year follow-up data demonstrate that a subset of patients with R/R HL who obtained CR with single-agent brentuximab vedotin achieved long-term disease control and may potentially be cured. The trial was registered at www.clinicaltrials.gov as #NCT00848926.

UR - http://www.scopus.com/inward/record.url?scp=84988697937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988697937&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-02-699850

DO - 10.1182/blood-2016-02-699850

M3 - Article

C2 - 27432875

AN - SCOPUS:84988697937

VL - 128

SP - 1562

EP - 1566

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -